

Richard K Plemper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8155021/publications.pdf>

Version: 2024-02-01

94
papers

4,396
citations

81900

39
h-index

123424

61
g-index

103
all docs

103
docs citations

103
times ranked

4666
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. <i>Nature Microbiology</i> , 2021, 6, 11-18.	13.3	323
2	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	253
3	Tunable and reversible drug control of protein production via a self-excising degron. <i>Nature Chemical Biology</i> , 2015, 11, 713-720.	8.0	180
4	Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	162
5	A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. <i>Virology</i> , 2012, 434, 129-136.	2.4	120
6	Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen. <i>Journal of Virology</i> , 2001, 75, 2087-2096.	3.4	119
7	Promotion of virus assembly and organization by the measles virus matrix protein. <i>Nature Communications</i> , 2018, 9, 1736.	12.8	114
8	Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. <i>Journal of Virology</i> , 2002, 76, 5051-5061.	3.4	111
9	Segmented Filamentous Bacteria Prevent and Cure Rotavirus Infection. <i>Cell</i> , 2019, 179, 644-658.e13.	28.9	106
10	Measles Virus Envelope Glycoproteins Hetero-oligomerize in the Endoplasmic Reticulum. <i>Journal of Biological Chemistry</i> , 2001, 276, 44239-44246.	3.4	97
11	Cell entry of enveloped viruses. <i>Current Opinion in Virology</i> , 2011, 1, 92-100.	5.4	94
12	Functional Interaction between Paramyxovirus Fusion and Attachment Proteins. <i>Journal of Biological Chemistry</i> , 2008, 283, 16561-16572.	3.4	93
13	Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. <i>Translational Research</i> , 2020, 218, 16-28.	5.0	90
14	Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics. <i>International Journal of Molecular Sciences</i> , 2011, 12, 4027-4052.	4.1	79
15	A target site for template-based design of measles virus entry inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5628-5633.	7.1	78
16	Probing the Spatial Organization of Measles Virus Fusion Complexes. <i>Journal of Virology</i> , 2009, 83, 10480-10493.	3.4	78
17	Structural and Mechanistic Studies of Measles Virus Illuminate Paramyxovirus Entry. <i>PLoS Pathogens</i> , 2011, 7, e1002058.	4.7	75
18	Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. <i>Nature Communications</i> , 2021, 12, 6415.	12.8	74

#	ARTICLE	IF	CITATIONS
19	Structure and organization of paramyxovirus particles. <i>Current Opinion in Virology</i> , 2017, 24, 105-114.	5.4	67
20	Nonpeptide Inhibitors of Measles Virus Entry. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5080-5092.	6.4	65
21	Characterization of a Region of the Measles Virus Hemagglutinin Sufficient for Its Dimerization. <i>Journal of Virology</i> , 2000, 74, 6485-6493.	3.4	64
22	Structural Rearrangements of the Central Region of the Morbillivirus Attachment Protein Stalk Domain Trigger F Protein Refolding for Membrane Fusion. <i>Journal of Biological Chemistry</i> , 2012, 287, 16324-16334.	3.4	63
23	Triggering the measles virus membrane fusion machinery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3018-27.	7.1	63
24	A Stabilized Headless Measles Virus Attachment Protein Stalk Efficiently Triggers Membrane Fusion. <i>Journal of Virology</i> , 2013, 87, 11693-11703.	3.4	62
25	Polymerases of paramyxoviruses and pneumoviruses. <i>Virus Research</i> , 2017, 234, 87-102.	2.2	59
26	4-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. <i>Science</i> , 2022, 375, 161-167.	12.6	58
27	Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5199-5203.	2.2	54
28	Mechanism for Active Membrane Fusion Triggering by Morbillivirus Attachment Protein. <i>Journal of Virology</i> , 2013, 87, 314-326.	3.4	54
29	Mutations in the Putative HR-C Region of the Measles Virus F Glycoprotein Modulate Syncytium Formation. <i>Journal of Virology</i> , 2003, 77, 4181-4190.	3.4	52
30	Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3755-3761.	3.2	52
31	Blue Native PAGE and Biomolecular Complementation Reveal a Tetrameric or Higher-Order Oligomer Organization of the Physiological Measles Virus Attachment Protein H. <i>Journal of Virology</i> , 2010, 84, 12174-12184.	3.4	52
32	An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model. <i>Science Translational Medicine</i> , 2014, 6, 232ra52.	12.4	52
33	Two Domains That Control Prefusion Stability and Transport Competence of the Measles Virus Fusion Protein. <i>Journal of Virology</i> , 2006, 80, 1524-1536.	3.4	48
34	Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2293-2303.	3.2	48
35	Independent Structural Domains in Paramyxovirus Polymerase Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 6878-6891.	3.4	47
36	Functional and Structural Characterization of Neutralizing Epitopes of Measles Virus Hemagglutinin Protein. <i>Journal of Virology</i> , 2013, 87, 666-675.	3.4	45

#	ARTICLE	IF	CITATIONS
37	Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis. <i>Journal of Virology</i> , 2015, 89, 512-522.	3.4	44
38	Next-generation direct-acting influenza therapeutics. <i>Translational Research</i> , 2020, 220, 33-42.	5.0	43
39	Structural Features of Paramyxovirus F Protein Required for Fusion Initiation. <i>Biochemistry</i> , 2003, 42, 6645-6655.	2.5	42
40	The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. <i>Frontiers in Microbiology</i> , 2015, 6, 459.	3.5	40
41	A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness. <i>PLoS Computational Biology</i> , 2020, 16, e1008451.	3.2	40
42	Non-nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase: Synthesis, Structure-Activity Relationships, and Pharmacokinetics. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4220-4230.	6.4	39
43	Potent Host-Directed Small-Molecule Inhibitors of Myxovirus RNA-Dependent RNA-Polymerases. <i>PLoS ONE</i> , 2011, 6, e20069.	2.5	39
44	Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. <i>Biochemistry</i> , 2015, 54, 5589-5604.	2.5	38
45	Potent Non-Nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase Complex. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3731-3741.	6.4	36
46	Molecular Determinants Defining the Triggering Range of Prefusion F Complexes of Canine Distemper Virus. <i>Journal of Virology</i> , 2014, 88, 2951-2966.	3.4	36
47	Sequential Conformational Changes in the Morbillivirus Attachment Protein Initiate the Membrane Fusion Process. <i>PLoS Pathogens</i> , 2015, 11, e1004880.	4.7	35
48	The Measles Virus Nucleocapsid Protein Tail Domain Is Dispensable for Viral Polymerase Recruitment and Activity. <i>Journal of Biological Chemistry</i> , 2013, 288, 29943-29953.	3.4	34
49	Reversible Inhibition of the Fusion Activity of Measles Virus F Protein by an Engineered Intersubunit Disulfide Bridge. <i>Journal of Virology</i> , 2007, 81, 8821-8826.	3.4	31
50	Target Analysis of the Experimental Measles Therapeutic AS-136A. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3860-3870.	3.2	31
51	The structurally disordered paramyxovirus nucleocapsid protein tail domain is a regulator of the mRNA transcription gradient. <i>Science Advances</i> , 2017, 3, e1602350.	10.3	29
52	Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. <i>Current Opinion in Virology</i> , 2019, 35, 1-13.	5.4	28
53	Measles Virus Glycoprotein Complexes Preassemble Intracellularly and Relax during Transport to the Cell Surface in Preparation for Fusion. <i>Journal of Virology</i> , 2015, 89, 1230-1241.	3.4	25
54	Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening. <i>Journal of Virology</i> , 2016, 90, 7368-7387.	3.4	25

#	ARTICLE	IF	CITATIONS
55	Progress and pitfalls of a year of drug repurposing screens against COVID-19. <i>Current Opinion in Virology</i> , 2021, 49, 183-193.	5.4	25
56	Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	25
57	Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10314-10328.	6.4	23
58	The Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain Modulates Viral Pathogenesis through Regulation of Transcriptase Activity. <i>Journal of Virology</i> , 2018, 92, .	3.4	23
59	Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. <i>Journal of Biological Chemistry</i> , 2018, 293, 16761-16777.	3.4	23
60	Measles Virus Entry Inhibitors: A Structural Proposal for Mechanism of Action and the Development of Resistance. <i>Biochemistry</i> , 2008, 47, 13573-13583.	2.5	22
61	Structure-guided design of small-molecule therapeutics against RSV disease. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 543-556.	5.0	20
62	Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy- D-Phe-L-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide. <i>Journal of Virology</i> , 2017, 91, .	3.4	20
63	Measles Resurgence and Drug Development. <i>Current Opinion in Virology</i> , 2020, 41, 8-17.	5.4	20
64	Measles control--can measles virus inhibitors make a difference?. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 811-20.	2.3	20
65	Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. <i>Nature Microbiology</i> , 2020, 5, 1232-1246.	13.3	18
66	Dual Myxovirus Screen Identifies a Small-Molecule Agonist of the Host Antiviral Response. <i>Journal of Virology</i> , 2013, 87, 11076-11087.	3.4	17
67	Synergizing vaccinations with therapeutics for measles eradication. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 201-214.	5.0	17
68	Capturing Enveloped Viruses on Affinity Grids for Downstream Cryo-Electron Microscopy Applications. <i>Microscopy and Microanalysis</i> , 2014, 20, 164-174.	0.4	17
69	Host-Directed Inhibitors of Myxoviruses: Synthesis and in Vitro Biochemical Evaluation. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 798-803.	2.8	15
70	Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex. <i>Viruses</i> , 2016, 8, 251.	3.3	15
71	Bipartite interface of the measles virus phosphoprotein X domain with the large polymerase protein regulates viral polymerase dynamics. <i>PLoS Pathogens</i> , 2019, 15, e1007995.	4.7	15
72	Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity. <i>PLoS Pathogens</i> , 2021, 17, e1009371.	4.7	13

#	ARTICLE	IF	CITATIONS
73	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>. <i>Journal of Virology</i> , 2021, 95, e0112621.	3.4	13
74	Canine Distemper Virus Envelope Protein Interactions Modulated by Hydrophobic Residues in the Fusion Protein Globular Head. <i>Journal of Virology</i> , 2015, 89, 1445-1451.	3.4	12
75	Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition. <i>Viruses</i> , 2020, 12, 342.	3.3	12
76	Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor. <i>Virus Research</i> , 2019, 259, 28-37.	2.2	10
77	Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2305-2325.	6.4	9
78	Biology must develop herd immunity against bad-actor molecules. <i>PLoS Pathogens</i> , 2018, 14, e1007038.	4.7	9
79	Viral evolution identifies a regulatory interface between paramyxovirus polymerase complex and nucleocapsid that controls replication dynamics. <i>Science Advances</i> , 2020, 6, eaaz1590.	10.3	9
80	Blocking Respiratory Syncytial Virus Entry: A Story with Twists. <i>DNA and Cell Biology</i> , 2015, 34, 505-510.	1.9	6
81	Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. <i>Nature Communications</i> , 2021, 12, 5233.	12.8	6
82	Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase. <i>Science Advances</i> , 2022, 8, .	10.3	6
83	Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
84	Protein Degradation in Human Disease. <i>Progress in Molecular and Subcellular Biology</i> , 2002, 29, 61-84.	1.6	5
85	4â€²-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness. <i>DNA and Cell Biology</i> , 2022, 41, 699-704.	1.9	5
86	Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses. <i>Current Opinion in Virology</i> , 2019, 35, iii-v.	5.4	2
87	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	5.4	2
88	4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. <i>Science</i> , 2021, , eabj5508.	12.6	2
89	Editorial overview: Special issue on antiviral strategies in <i>Current Opinion in Virology</i> . <i>Current Opinion in Virology</i> , 2021, 50, 95-96.	5.4	1
90	Targeting Measles Virus Entry. , 2003, , 321-336.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2020, 16, e1008451.		0
92	Title is missing!. , 2020, 16, e1008451.		0
93	Title is missing!.. , 2020, 16, e1008451.		0
94	Title is missing!.. , 2020, 16, e1008451.		0